Imatinib is the standard first line treatment for chronic myeloid leukemia(CML).Owing to doserelated toxicities of Imatinib such as neutropenia,there is scope for treatment optimization through therapeutic drug monito...Imatinib is the standard first line treatment for chronic myeloid leukemia(CML).Owing to doserelated toxicities of Imatinib such as neutropenia,there is scope for treatment optimization through therapeutic drug monitoring(TDM).Trough concentration of 1g/mL is considered the therapeutic threshhold.Existing methods for the detection of Imatinib in plasma are limited by long read out time and expensive instrumentation.Hence,Raman spectroscopy was explored as a rapid and objective tool for monitoring Imatinib concentration.Three approaches:conventional Raman spectroscopy(CRS),Drop coating deposition Raman(DCDR)spectroscopy and surface-enhanced Raman spectroscopy(SERS)were employed to detect the required trough concentration of 1g/mL and above.Detection of therapeutically relevant concentrations(1g/mL)using SERS and suitable nanoparticle substrates has been demonstrated.Prospectively,rigorous validation using clinical samples is necessary to confirm the utility of this approach in routine clinical usage.展开更多
Breast cancer is one of the leading causes of cancer-related deaths in a global scenario.In the present study,biochemical changes exerted upon Pentoxifylline(PTX)treatment had been ap-praised in human breast cancer ce...Breast cancer is one of the leading causes of cancer-related deaths in a global scenario.In the present study,biochemical changes exerted upon Pentoxifylline(PTX)treatment had been ap-praised in human breast cancer cells using Raman spectrosecopy.There are no clinically approved methods to monitor such therapeutic responses available.The spectral profiling is suggestive of changes in DNA,protein and lipid contents showing a linear relationship with drug dosage.Further,multivariate analysis using principal component based linear-discriminant-analysis(PC-LDA)was employed for dlassifying the control and the PTX treated groups.These findings support the feasibility of Raman spectroscopy as an alternate/adjunct label-free,objective method for monitoring drug-induced modifications against breast cancer cells.展开更多
Concurrent chemoradiotherapy(CCRT)is the choice of treatment for locally adv anced cervical cancers;however,tumors exhibit diverse response to treatment.Early prediction of tumor response leads to individualizing trea...Concurrent chemoradiotherapy(CCRT)is the choice of treatment for locally adv anced cervical cancers;however,tumors exhibit diverse response to treatment.Early prediction of tumor response leads to individualizing treatment regimen.Response evaluation criteria in solid tumors(RECIST),the current modality of tumor response assessment,is often subject ive and carried out at the first visit after treatment,which is about four months.Hence,there is a need for better predictive tool for radioresponse.Optical spectroscopic techniques,sensitive to molecular alteration,are being pursued as potential diagnostic tools.Present pilot study ains to explore the fiber-optic-based Raman spectroscopy approach in prediction of tumor response to CCRT,before taking up extensive in vivo studies.Ex vivo Raman spectra were acquired from biopsies collected from 11 normal(148 spectra),16 tumor(201 spectra)and 13 complete response(151 CR spectra),one partial response(8 PR spectra)and one nonresponder(8 NR spectra)subjects.Data was analyzed using principal component linear discriminant analysis(PC-LDA)followed by leave-one-out cross-validation(LOO-CV).Findings suggest that normal tissues can be efficiently classified from both pre-and post-treated tumor biopsies,while there is an overlap between pre-and post-CCRT tumor tissues.Spectra of CR,PR and NR tissues were subjected to principal component analysis(PCA)and a tendency of classification was observed,corroborating previous studies.Thus,this study further supports the feasibility of Raman spectroscopy in prediction of tumor radioresponse and prospective noninvasive in vivo applications.展开更多
文摘Imatinib is the standard first line treatment for chronic myeloid leukemia(CML).Owing to doserelated toxicities of Imatinib such as neutropenia,there is scope for treatment optimization through therapeutic drug monitoring(TDM).Trough concentration of 1g/mL is considered the therapeutic threshhold.Existing methods for the detection of Imatinib in plasma are limited by long read out time and expensive instrumentation.Hence,Raman spectroscopy was explored as a rapid and objective tool for monitoring Imatinib concentration.Three approaches:conventional Raman spectroscopy(CRS),Drop coating deposition Raman(DCDR)spectroscopy and surface-enhanced Raman spectroscopy(SERS)were employed to detect the required trough concentration of 1g/mL and above.Detection of therapeutically relevant concentrations(1g/mL)using SERS and suitable nanoparticle substrates has been demonstrated.Prospectively,rigorous validation using clinical samples is necessary to confirm the utility of this approach in routine clinical usage.
基金support from ACTREC,Tata Memorial Centresupported by CSIR-Senior Research fellowship+1 种基金supported by ACTREC Senior Research fellowshipprocured from DBT project BT/PRI11282/MED/32/83/2008,entitled\Development of in vivo laser Raman spectroscopy methods for diagnosis of oral precancerous and cancerous conditions,Department of Biotechnology,Government of India".
文摘Breast cancer is one of the leading causes of cancer-related deaths in a global scenario.In the present study,biochemical changes exerted upon Pentoxifylline(PTX)treatment had been ap-praised in human breast cancer cells using Raman spectrosecopy.There are no clinically approved methods to monitor such therapeutic responses available.The spectral profiling is suggestive of changes in DNA,protein and lipid contents showing a linear relationship with drug dosage.Further,multivariate analysis using principal component based linear-discriminant-analysis(PC-LDA)was employed for dlassifying the control and the PTX treated groups.These findings support the feasibility of Raman spectroscopy as an alternate/adjunct label-free,objective method for monitoring drug-induced modifications against breast cancer cells.
文摘Concurrent chemoradiotherapy(CCRT)is the choice of treatment for locally adv anced cervical cancers;however,tumors exhibit diverse response to treatment.Early prediction of tumor response leads to individualizing treatment regimen.Response evaluation criteria in solid tumors(RECIST),the current modality of tumor response assessment,is often subject ive and carried out at the first visit after treatment,which is about four months.Hence,there is a need for better predictive tool for radioresponse.Optical spectroscopic techniques,sensitive to molecular alteration,are being pursued as potential diagnostic tools.Present pilot study ains to explore the fiber-optic-based Raman spectroscopy approach in prediction of tumor response to CCRT,before taking up extensive in vivo studies.Ex vivo Raman spectra were acquired from biopsies collected from 11 normal(148 spectra),16 tumor(201 spectra)and 13 complete response(151 CR spectra),one partial response(8 PR spectra)and one nonresponder(8 NR spectra)subjects.Data was analyzed using principal component linear discriminant analysis(PC-LDA)followed by leave-one-out cross-validation(LOO-CV).Findings suggest that normal tissues can be efficiently classified from both pre-and post-treated tumor biopsies,while there is an overlap between pre-and post-CCRT tumor tissues.Spectra of CR,PR and NR tissues were subjected to principal component analysis(PCA)and a tendency of classification was observed,corroborating previous studies.Thus,this study further supports the feasibility of Raman spectroscopy in prediction of tumor radioresponse and prospective noninvasive in vivo applications.
